Literature DB >> 8650589

Mortality in rheumatoid arthritis.

R A Myllykangas-Luosujärvi1, K Aho, H A Isomäki.   

Abstract

Patients with rheumatoid arthritis (RA) have a substantially reduced life expectancy. The standardized mortality ratio in different studies has ranged from 1.13 to 2.98. This mainly applies to rheumatoid factor (RF)-positive cases, although there is a subgroup of RF-negative cases with an adverse long-term prognosis. Clinically based studies probably overestimate the true shortening of life span and population-based studies may underestimate it. Excess mortality from infection and from renal disease likely reflects the presence of severe disease, whereas most of the added mortality from gastrointestinal causes is treatment related. The reasons for the surplus of mortality from cardiovascular causes are not fully known. RF may have a direct role, and preillness factors such as smoking may predipose patients to RA and also render them susceptible to cardiovascular diseases. The excess mortality associated with RA is appreciably higher than is apparent from the cases in which RA is regarded as an underlying cause of death. The effect of treatment on mortality remains largely unknown.

Entities:  

Mesh:

Year:  1995        PMID: 8650589     DOI: 10.1016/s0049-0172(95)80031-x

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  24 in total

Review 1.  Does hemopoietic stem cell transplantation have a role in treatment of severe rheumatoid arthritis?

Authors:  R M Lowenthal; S R Graham
Journal:  J Clin Immunol       Date:  2000-01       Impact factor: 8.317

Review 2.  Rheumatoid arthritis in women: still associated with an increased mortality.

Authors:  N Goodson; D Symmons
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

3.  Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities.

Authors:  A Kuryliszyn-Moskal
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

4.  Clinical significance of antibodies against oxidised low density lipoprotein in early RA.

Authors:  L Paimela; T Helve; M Leirisalo-Repo; O Vaarala; G Alfthan; T Palosuo; K Aho
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

5.  Dyslipidemia and rheumatoid arthritis.

Authors:  R D Situnayake; G Kitas
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

Review 6.  The role of endothelial function and its assessment in rheumatoid arthritis.

Authors:  Faisel Khan; Bernat Galarraga; Jill J F Belch
Journal:  Nat Rev Rheumatol       Date:  2010-03-30       Impact factor: 20.543

7.  Objective assessment of abnormal gait in patients with rheumatoid arthritis using a smartphone.

Authors:  Minoru Yamada; Tomoki Aoyama; Shuhei Mori; Shu Nishiguchi; Kazuya Okamoto; Tatsuaki Ito; Shinyo Muto; Tatsuya Ishihara; Hiroyuki Yoshitomi; Hiromu Ito
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

8.  Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis.

Authors:  R Peltomaa; L Paimela; H Kautiainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

9.  Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis.

Authors:  Michelle J Ormseth; Aliza Lipson; Nikolaos Alexopoulos; Gregory R Hartlage; Annette M Oeser; Aihua Bian; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; C Michael Stein
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-09       Impact factor: 4.794

Review 10.  Cardiovascular morbidity and mortality in rheumatoid arthritis.

Authors:  Sherine E Gabriel
Journal:  Am J Med       Date:  2008-10       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.